Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SCHOTT Pharma AG & Co. KGaA (1SXP.F)
Mainz, DE
Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.26% | +5.64% | +14.76% | +10.01% | -13.26% | +11.96% | -36.62% | -47.35% | -47.35% | -47.35% | -47.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+3.0% Q1'26: -1.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-2.0% Q1'26: -19.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+8.6% Q1'26: +26.3% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+19.6% ★ Q1'26: +14.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+15.9% ★ Q1'26: +12.3% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.30× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 9 Rev. Ana. 2 EPS Ana. |
Sep 2027 11 Rev. Ana. 9 EPS Ana. |
Sep 2028 8 Rev. Ana. 6 EPS Ana. |
Sep 2029 4 Rev. Ana. 3 EPS Ana. |
Sep 2030 4 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
898.60M
est: 916.32M (-1.9%)
|
957.09M
est: 961.03M (-0.4%)
|
986.21M
est: 987.36M (-0.1%)
|
1.01B
1.00B – 1.02B
+2.5% YoY
|
1.08B
1.05B – 1.11B
+6.8% YoY
|
1.15B
1.15B – 1.16B
+6.6% YoY
|
1.22B
1.20B – 1.24B
+5.8% YoY
|
1.29B
1.27B – 1.32B
+6.1% YoY
|
| EBITDA |
232.84M
est: 283.13M (-17.8%)
|
262.44M
est: 296.95M (-11.6%)
|
273.06M
est: 305.08M (-10.5%)
|
312.61M
310.38M – 315.29M
+2.5% YoY
|
333.98M
324.39M – 342.56M
+6.8% YoY
|
356.01M
355.03M – 357.00M
+6.6% YoY
|
376.59M
369.70M – 383.16M
+5.8% YoY
|
399.58M
392.27M – 406.55M
+6.1% YoY
|
| EBIT |
181.00M
est: 187.96M (-3.7%)
|
197.46M
est: 197.13M (+0.2%)
|
193.62M
est: 202.54M (-4.4%)
|
207.54M
206.05M – 209.31M
+2.5% YoY
|
221.72M
215.35M – 227.41M
+6.8% YoY
|
236.35M
235.69M – 237.00M
+6.6% YoY
|
250.01M
245.43M – 254.37M
+5.8% YoY
|
265.27M
260.42M – 269.90M
+6.1% YoY
|
| Net Income |
151.84M
est: 134.63M (+12.8%)
|
149.69M
est: 147.57M (+1.4%)
|
146.45M
est: 149.95M (-2.3%)
|
142.61M
139.61M – 145.61M
-4.9% YoY
|
162.85M
150.75M – 186.16M
+14.2% YoY
|
181.43M
170.42M – 195.63M
+11.4% YoY
|
191.42M
186.87M – 195.76M
+5.5% YoY
|
213.54M
208.46M – 218.38M
+11.6% YoY
|
| SGA |
122.09M
est: 123.46M (-1.1%)
|
124.48M
est: 129.48M (-3.9%)
|
129.88M
est: 133.03M (-2.4%)
|
136.32M
135.34M – 137.48M
+2.5% YoY
|
145.63M
141.45M – 149.37M
+6.8% YoY
|
155.24M
154.81M – 155.67M
+6.6% YoY
|
164.21M
161.21M – 167.08M
+5.8% YoY
|
174.24M
171.05M – 177.28M
+6.1% YoY
|
| EPS |
1.01
est: 0.89 (+13.6%)
|
0.99
est: 0.98 (+1.3%)
|
0.97
est: 1.00 (-2.6%)
|
0.95
0.93 – 0.97
-4.9% YoY
|
1.07
1.00 – 1.24
+13.0% YoY
|
1.20
1.13 – 1.30
+11.9% YoY
|
1.27
1.24 – 1.30
+6.1% YoY
|
1.42
1.38 – 1.45
+11.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi SDAX UCITS ETF Dist C005.DE | 1.54% | 2.75M | 0.70% |
| 2 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.30% | 2.15M | 0.40% |
| 3 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.14% | 1.43M | 0.58% |
| 4 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.13% | 974.7K | 0.33% |
| 5 | Amundi F.A.Z. 100 UCITS ETF Dist C006.DE | 0.12% | 136.2K | 0.15% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.11% | 372.3K | 0.23% |
| 7 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.11% | 372.3K | 0.23% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.05% | 88.9K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.04% | 1.47M | 0.30% |
| 10 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.04% | 307.5K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andreas Reisse | Chairperson of Management Board & Chief Executive Officer of SCHOTT Pharma Management AG | 1M | male |
| Reinhard Josef Mayer | Member of Management Board & Chief Financial Officer of SCHOTT Pharma Management AG | 677.0K | male |
| Arne Kloke | Head of Service & Sustainability Management | — | — |
| Christian Mias | Chief Executive Officer | — | male |
| Isabelle Jeangoudoux | Head of Global Product Management | — | — |
| Tobias Erfurth | Head of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1SXP.F
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
